List Labs Bacterial Toxin & Vaccine Research Blog

Bacterially Derived Therapeutic Proteins: Why Early Process Strategy Matters

July 28, 2026

By: List Labs

Bacterially Derived Therapeutic Proteins: Why Early Process Strategy Matters By Kent Davis, and John Neville, PhD List Labs July 2026 Bacterial expression systems remain one of the most important platforms for producing therapeutic proteins, bacterial-derived proteins, toxins, toxoids, enzymes, vaccine components, and other biologically active molecules. Their speed, scalability, well-understood genetics, and long history of [...]

Read more

C. difficile Toxin A and Toxin B: Roles in CDI Research, Diagnostics, Vaccines, and Therapeutics

June 22, 2026

By: List Labs

C. difficile Toxin A and Toxin B: Roles in CDI Research, Diagnostics, Vaccines, and Therapeutics By Stacy Burns-Guydish, PhD, and John Neville, PhD List Labs Clostridioides difficile infection is primarily driven by toxin-mediated damage caused by toxin A and toxin B, also known as TcdA and TcdB. These toxins are central to CDI pathogenesis and [...]

Read more

Navigating the Complexities of Microbiological Testing for Live Biotherapeutic Products (LBPs)

August 7, 2025

By: List Labs

Navigating the Complexities of Microbiological Testing for Live Biotherapeutic Products (LBPs) By: Sarah Henning Senior Manager, Quality Control List Labs Live Biotherapeutic Products (LBPs) are emerging as powerful tools in the fight against chronic illness, infections, and even cancer. These living microbial therapeutics hold immense promise—but their very nature presents unique challenges, particularly when it […]

Read more

Why Standard Microbial Tests Fail for Live Biotherapeutics

August 5, 2025

By: List Labs

Why Standard Microbial Tests Fail for Live Biotherapeutics By: Sarah Henning Senior Manager, Quality Control List Labs As the field of live biotherapeutic products (LBPs) rapidly advances, so too does the need for rigorous, nuanced microbiological quality control (QC). LBPs—live microorganisms used to prevent, treat, or cure diseases—present unique challenges when meeting regulatory safety standards. […]

Read more

6 Common Pitfalls in CDMO Partnerships—and How to Avoid Them

March 18, 2025

By: Gary Henderson

6 Common Pitfalls in CDMO Partnerships—and How to Avoid Them Intro From small biotech startups to global pharmaceutical giants, many companies rely on Contract Development and Manufacturing Organizations (CDMOs) to bring their products to market more efficiently. Outsourcing can accelerate timelines and reduce up-front investment in facilities, but it also brings risks if not managed […]

Read more

A Legacy of Excellence in Bacterial Production

June 23, 2023

By: List Labs

Reasons to choose List Labs as your Microbiome CDMO: We support a very diverse offering in Bacterial Manufacturing. We are a passionate and transparent CDMO. We are flexible and cohesive enough to be an extension of our customer's team. We offer end-to-end solutions for our customers. Learn more about List Labs' 45 years of experience [...]

Read more